Therapeutics: Tumor necrosis factor (TNF) receptor superfamily member 10c (TNFRSF10C; TRAIL-R3; CD263)

Cell culture and mouse studies suggest combining CD263 inhibition with temozolomide could help treat glioblastoma. In a human glioblastoma cell line, temozolomide increased transcript and protein levels of CD263 compared with vehicle. Also in the cell line, temozolomide plus siRNA against CD263 increased markers of apoptosis compared with the siRNA alone or temozolomide plus a scrambled siRNA. In mice with intracranial xenograft glioblastomal tumors, temozolomide plus nanoparticles loaded with siRNA against CD263 increased survival compared with either agent alone or temozolomide plus nanoparticles loaded with scrambled siRNA. Next steps could include screening for small molecule inhibitors of CD263...